Related Experiment Video

Updated: Mar 29, 2026

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

7.2K

MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer

Andrea Mathe1,2, Rodney J Scott3,4,5, Kelly A Avery-Kiejda6,7

  • 1Centre for Information Based Medicine, Hunter Medical Research Institute, Newcastle, NSW 2305, Australia. andrea.mathe@uon.edu.au.

International Journal of Molecular Sciences
|December 4, 2015
PubMed

Insights

Triple negative breast cancer (TNBC) lacks key receptors, making it hard to treat. MicroRNAs show promise as biomarkers and therapeutic targets for this aggressive cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Triple negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors.
  • TNBC has an aggressive nature and poor prognosis, necessitating novel treatment strategies.
  • Current treatments for TNBC are limited to chemotherapy, radiotherapy, and surgery.

Purpose of the Study:

  • To review current knowledge on microRNAs (miRNAs) as biomarkers for TNBC.
  • To explore the potential of miRNAs as therapeutic targets in TNBC.
  • To examine epigenetic changes and their interaction with miRNAs in TNBC for new treatment discovery.

Main Methods:

  • Literature review of current research on miRNAs and TNBC.
  • Analysis of miRNA roles in gene regulation and malignancy.
  • Investigation of epigenetic modifications in breast cancer subtypes.

Main Results:

  • MicroRNAs are effective regulators of gene sets involved in malignancy.
  • miRNAs demonstrate superiority over mRNA profiling for accurate disease classification.
  • Epigenetic changes, interacting with miRNAs, offer potential new therapeutic avenues.

Conclusions:

  • MicroRNAs are promising biomarkers for TNBC diagnosis and prognosis.
  • Targeting miRNAs presents a viable therapeutic strategy for TNBC.
  • Further research into miRNA-epigenetic interactions may uncover novel TNBC treatments.
Keywords:
DNA methylationmicroRNAtriple negative breast cancer

More Related Videos

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.8K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K